Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Debiopharm Group™ and Aurigene Nominate Development Candidate

September 13, 2010 By Bio-Medicine.Org

LAUSANNE, Switzerland, and BANGALORE, India, Sept. 13
/PRNewswire/ — Debiopharm Group™ (Debiopharm), a Swiss-based
global biopharmaceutical group of companies with a focus on the
development of innovative prescription drugs that target unmet
medical needs, and Aurigene Discovery Technologies Ltd. (Aurigene),
a Bangalore-based fully integrated, global biotech focused on small
molecule and peptide drug discovery and development from target
identification and validation to pre-IND drug candidates, today
announced the successful nomination of a development candidate,
Debio 0617, a novel inhibitor of an undisclosed oncology pathway.
Debio 0617 has started IND enabling studies and is expected to
enter clinical development in 2012.

Debiopharm and Aurigene have been collaborating for five years.
In November 2008, Aurigene’s fragment-based drug delivery
technology platform had generated potent leads against the target.
Both companies signed an exclusive worldwide license agreement,
excluding the territories of Japan and the rest of Asia, to develop
and commercialise Debio 0617. They defined a target molecular
profile at the beginning of the program. Now, 20 months later, both
teams have successfully identified the development candidate which
better fits the initial target molecular profile.

“What exciting news! As we expected, this program has delivered
a development candidate molecule as well as several potential
follow-on compounds,” said Rolland-Yves Mauvernay, president and
founder of Debiopharm Group™. “Once again, Aurigene has
demonstrated its dedication and professionalism.”

“This represents an important success not just for this
scientific program, but also for the strategic path that was
established through this agreement between Debiopharm and Aurigene.
This is a truly synergistic relationship that takes advantage of
the proven experience, expertise and processes at Debiopharm,
coupled with the speed, flexibility and high-qualit

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech